ZBP1 and melanoma: As a proof-of-concept that the biomarkers we identified could be translated into potential therapeutic targets, we treated melanoma cells with combination therapy that activates ZBP1 (17) and showed that this treatment induced PANoptosis to kill the cancer cells.